Nyxoah S.A.(NYXH)

Medical - Specialties · Mont-Saint-Guibert, WA

$1.44+0.03 (+1.77%)

Delayed quote: Oct 6, 2026, 2:49 PM EDT

EV/EBIT Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBIT ratio is N/A as of 2026-10-06T18:52:29.260Z.

Stored calculation inputs

Calculation as of: 2026-10-06T18:52:29.260Z.

Quote observation: 2026-10-06T18:49:25.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 143,604,490
Total debt · period ending 2026-06-30: 60,042,118.24
Cash · period ending 2026-06-30: 73,230,870.7
TTM operating income · period ending 2026-06-30: -100,768,730.21068001

FMP input reference: 88249fb6bbade3b4ad802b4bad00c79a42ee89cc3a650020707e3f27628c9d48

EV/EBITDA|EV/Sales|Operating Income|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

NYXH EV/EBIT Ratio Metrics

EV/EBIT RATIO

N/A

NYXH Competitors' EV/EBIT Ratio

NYXH

Nyxoah S.A.

Current

Market Cap

$143.60M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

TARA

Protara Therapeutics, Inc.

vs NYXH

Market Cap

$143.29M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

FBIOP

Fortress Biotech, Inc.

vs NYXH

Market Cap

$142.96M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

KRSA

Korsana Biosciences, Inc.

vs NYXH

Market Cap

$144.19M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

STRO

Sutro Biopharma, Inc.

vs NYXH

Market Cap

$142.06M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IMRX

Immuneering Corporation

vs NYXH

Market Cap

$140.67M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ABOS

Acumen Pharmaceuticals, Inc.

vs NYXH

Market Cap

$147.34M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CRDL

Cardiol Therapeutics Inc.

vs NYXH

Market Cap

$148.17M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ACOG

Alpha Cognition Inc

vs NYXH

Market Cap

$139.01M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

VYGR

Voyager Therapeutics, Inc.

vs NYXH

Market Cap

$148.33M

EV/EBIT Ratio

N/A

TTM Avg

18.14x

3Y Avg

8.57x

5Y Avg

7.17x

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
Nyxoah S.A. (NYXH)	$143.60M	N/A	N/A	N/A	N/A
Protara Therapeutics, Inc. (TARA)vs ›	$143.29M	N/A	N/A	N/A	N/A
Fortress Biotech, Inc. (FBIOP)vs ›	$142.96M	N/A	N/A	N/A	N/A
Korsana Biosciences, Inc. (KRSA)vs ›	$144.19M	N/A	N/A	N/A	N/A
Sutro Biopharma, Inc. (STRO)vs ›	$142.06M	N/A	N/A	N/A	N/A
Immuneering Corporation (IMRX)vs ›	$140.67M	N/A	N/A	N/A	N/A
Acumen Pharmaceuticals, Inc. (ABOS)vs ›	$147.34M	N/A	N/A	N/A	N/A
Cardiol Therapeutics Inc. (CRDL)vs ›	$148.17M	N/A	N/A	N/A	N/A
Alpha Cognition Inc (ACOG)vs ›	$139.01M	N/A	N/A	N/A	N/A
Voyager Therapeutics, Inc. (VYGR)vs ›	$148.33M	N/A	18.14x	8.57x	7.17x

EV/EBIT Ratio Formula & Definition

EV/EBIT = Enterprise Value / EBIT (TTM)

Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/EBIT Ratio: N/A

NYXH EV/EBIT Ratio Metrics

NYXH Competitors' EV/EBIT Ratio

EV/EBIT Ratio Formula & Definition

Related Metrics